Welcome back. The Centers for Medicare and Medicaid Services just announcing lower negotiated prices on a slew of prescription drugs including the weight loss drugs ompic and WGO. Bertha Kums has the story for us.Bertha, >> hey David. Uh there are 15 drugs that were on the list for discounts in Medicare starting in 2027 and on average the Trump administration negotiated prices that are about 36% below the net price paid by Medicare back in 2024. Now that compares to about a 22% net discount for the first ro ...

We've got breaking news on drug pricing out of the CMS. Bertha Kums has got the details. Bertha, >> that's right, Melissa.The Centers for Medicare and Medicaid out with their inflation reduction act negotiated prices. These are the companies in the uh drugs that will be at these prices starting in 2027 in Medicare Part D. One of the biggest uh categories is diabetes of course, Goi, Rebelsis.In that uh cohort, the negotiated price is $274. at 71% below uh the list price but of course we know the MFN price is ...

The White House has struck a deal with two more drugmakers: Eli Lilly and Novo Nordisk. Centers for Medicare and Medicaid Services administrator Dr. Mehmet Oz discusses the administration’s plan to make GLP-1s more affordable for Americans. Tesla shareholders voted to approve Elon Musk’s $1 trillion pay package, as long as he reaches their lofty goals for the company. Musk biographer Walter Isaacson discusses the plan of milestones and Musk’s history of exceeding investor expectations. Plus, U.S. airlines a ...

For more on all this, let's bring in Beimo head of healthc care research, Evan David Seager. Evan, great to have you with us. >> Thank you for having me.>> Um, this is really becoming a battle over Meter. Is Metera worth this much. And who is it worth more to, Novo or Fizer.>> Well, I think Metser is definitely worth this much. As you know, the obesity market is likely to be in our estimates upwards of $130 billion when you lump in diabetes. So, there is a big opportunity here.And right now, it's only Lily ...

Prices for older drugs don't always drop. The latest Prognosis newsletter looks at why, and how Trump's deals are leaving out some costly treatments https://t.co/E3teuk6bx6 ...

Old drugs usually go way down in price, but not all of them. Here’s one that has gotten a lot more expensive over its decades on the market https://t.co/TEyGjtGwdh ...

Core Insights - CVS Health's pharmacy benefit manager, CVS Caremark, is delaying the addition of Gilead Sciences' new HIV prevention drug, Yeztugo, to its formularies due to pricing issues [2] Group 1 - CVS Caremark is prioritizing pricing concerns over the inclusion of new drugs in its formularies [2] - The decision to hold off on Yeztugo's addition reflects ongoing challenges in managing drug costs within the pharmacy benefit management sector [2]

It was only 2022 when you launched cost plus. It seems as though we've been having this conversation for a long time. >> Yeah.>> So much has happened in those three years. >> Where do you feel you are. Are you where you thought cost plus would be.>> Honestly, from the day we launched with 111 medications, we're so much further than I ever expected. Um the response has just been through the roof. And realize we don't spend a nickel on advertising or marketing.It's all word of mouth and we've had I mean we've ...

As an example, in London, you'd buy a certain drug for $130 and even less than that, I guess $88 as of account a month ago. And in New York, you pay $1,300 for the same thing. So now we're going to be paying uh instead of 1300, you'll be paying about $150. And they'll be paying $150, too.We're going to pay the same thing. Favored nations. It's beautiful. It's a beautiful thing.and we've been ripped off by the whole world for a long period of time. >> You mentioned a $1,300 drug at the top of this. Were you ...

That was the president yesterday in a press conference with Dr. . Oz suggesting that out-of- pocket prices for Ozepic could soon be made lower. Shares of Eli Liy and Nova you can see under some pressure this morning as a result of those comments.Joining us now to break down the moveo healthc care strategist Jared Holes. So Jared, what do you make of those comments. What do they mean for either one of these key drug makers.>> Hey David, how are you. Um I'm not that surprised. I mean, this this seems like, yo ...